'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
August 17, 2011
'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders
November 30, 2011 / Pharmacogenomics Reporter - FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - Despite Passionate Patient Accounts, FDA Sees No Evidence of 'Super-Responders' in Avastin Trials
June 29, 2011 / Pharmacogenomics Reporter - Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
December 22, 2010 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter